WNK2 and melanoma: These findings, in addition to the discovery of melanoma driver mutation subsets and the important role that the mitogen-activated protein kinase pathway plays in a significant part of melanomas [10], have led to the approval of nine new treatments or combinations thereof since 2011 [3, 9, 11].